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Abstract
Background: Although mast cells are regarded as important regulators of inflammation and tissue remodelling,
their role in cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF) has remained less studied. This study
investigates the densities and phenotypes of mast cell populations in multiple lung compartments from patients
with CF, IPF and never smoking controls.
Methods: Small airways, pulmonary vessels, and lung parenchyma were subjected to detailed
immunohistochemical analyses using lungs from patients with CF (20 lung regions; 5 patients), IPF (21 regions; 7
patients) and controls (16 regions; 8 subjects). In each compartment the densities and distribution of MCT and
MCTC mast cell populations were studied as well as the mast cell expression of IL-6 and TGF-b.
Results: In the alveolar parenchyma in lungs from patients with CF, MCTC numbers increased in areas showing
cellular inflammation or fibrosis compared to controls. Apart from an altered balance between MCTC and MCT cells,
mast cell in CF lungs showed elevated expression of IL-6. In CF, a decrease in total mast cell numbers was
observed in small airways and pulmonary vessels. In patients with IPF, a significantly elevated MCTC density was
present in fibrotic areas of the alveolar parenchyma with increased mast cell expression of TGF-b. The total mast
cell density was unchanged in small airways and decreased in pulmonary vessels in IPF. Both the density, as well
as the percentage, of MCTC correlated positively with the degree of fibrosis. The increased density of MCTC, as well
as MCTC expression of TGF-b, correlated negatively with patient lung function.
Conclusions: The present study reveals that altered mast cell populations, with increased numbers of MCTC in
diseased alveolar parenchyma, represents a significant component of the histopathology in CF and IPF. The mast
cell alterations correlated to the degree of tissue remodelling and to lung function parameters. Further
investigations of mast cells in these diseases may open for new therapeutic strategies.
Keywords: mast cell, connective tissue mast cell, cystic fibrosis, idiopathic pulmonary fibrosis, alveolar parenchyma,
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Background
Mast cells release a vast range of cytokines, proteases and
proteoglycans that can modify and direct the inflammatory
response towards resolution or formation of fibrosis [1].
Mast cell-derived molecules can both modify the produc-
tion and destruction of extracellular matrix as well as
promote migration and proliferation of fibroblasts in vitro
[2-4]. Despite that mast cells have been shown to promote
fibrosis in several organs [5,6], their relationship to fibrotic
lesions and inflammatory foci in the lung has remained
poorly studied.
The present study involves assessment of mast cells in
cystic fibrosis (CF) and idiopathic pulmonary fibrosis
(IPF), diseases that have peripheral lung fibrosis as a signif-
icant pathological feature. The pathophysiological events
in CF are caused by mutations in the chloride channel
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lator (CFTR), leading to defective trans-epithelial ion
transport, airway surface liquid depletion, decreased
mucociliary clearance and mucus obstruction [7]. Due to
these effects decreased clearance of pathogens result in
chronic infections, which sustains inflammation and cause
lung remodelling and fibrosis [8]. In IPF the pathology is
characterised by epithelial damage, mild inflammation,
formation of fibroblast foci, and excessive extracellular
matrix deposition in the alveolar parenchyma [9,10].
Previous studies have reported presence of mast cells
in the airways of patients with CF [11,12] and increased
mast cell numbers in the airways of patients with IPF
[13-15]. However, information about the distribution
pattern and phenotypes of lung mast cells in these con-
ditions is lacking. Mast cells are traditionally divided
into two subtypes according to their granule content;
tryptase
+ and chymase
+ mast cells (MCTC: “connective
tissue mast cells”) and tryptase
+ but chymase
- mast cells
(MCT: “mucosal mast cells”), where the latter is the
most frequent in healthy lungs [16]. Recent data suggest
that the proportion of the MCTC population is increased
in inflammatory airway diseases like asthma and COPD
[17-19], and increased chymase expression has been
reported in human idiopathic interstitial pneumonia
[20,21].
In the present study we hypothesised that the mast
cell populations of the lung are significantly altered in
CF and IPF, and that this may contribute to the patho-
genesis of these disorders. The changes in MCT and
MCTC populations in CF and IPF were studied by histo-
logical assessment in key lung compartments and com-
pared to that in never-smoking control subjects. The
importance of exploring several anatomical regions is
underscored by the discovery that each of the MCT and
MCTC population can be divided into site-specific popu-
lations unique for each anatomical compartment [22].
The use of large surgical resections allowed us to com-
pare key compartments such as small airways and pul-
monary vessels and alveolar parenchymal regions
affected by severe cellular inflammation and/or parench-
ymal fibrosis. To get further insight into the MCT and
MCTC phenotypes in CF and IPF, mast cell expression
of mediators of importance in the inflammatory
responses and fibrosis (IL-6 and TGF-b), were analysed
in the same lung regions.
Methods
Subjects
CF was diagnosed on the basis of clinical manifestations
from the lung and gastro-intestinal tract and a positive
sweat test [23,24]. In 5 patients with end-stage CF, lung
tissues (20 large tissue blocks) were collected in associa-
tion with lung transplantation. The study also explored 21
large lung tissue blocks from 7 IPF patients, diagnosed
based on established criteria [9] and confirmed by open
lung biopsy. None of the IPF patients reported any envir-
onmental or occupational exposure and the patients were
untreated at the time of tissue collection (see Table 1).
A group with never-smoking subjects was used as controls
(n = 8) [17,22]. The control tissue was obtained during
lung lobectomy due to suspected lung cancer from other-
wise healthy non-atopic individuals [25,26]. Only patients
with solid (and typically centrally located) tumours were
included and the tissue for the present analysis was col-
lected from peripheral lung regions, as far from the
tumour as possible. All CF patients and control subjects
gave their written informed consent to participate in the
study, which was approved by the ethics committee in
Lund, Sweden (FEK 91/2006 and FEK 213/2005). The
research protocol for IPF patients, who gave written
informed consent to be included in the study, was
approved by the Ethics Committee of the National Insti-
tute of Respiratory Diseases, Mexico. For patient charac-
teristics, see Table 1.
Processing of Tissue and Histological Procedures
Lung tissue was dissected and sampled under controlled
circumstances in a study that was designed to collect tis-
sue from corresponding areas from each patient. To
guarantee optimal antigenicity, care was taken to
immerse the tissue in fixative immediately after surgical
excision and multiple large tissue blocks were prepared
for histological analysis. Lung tissue blocks were placed
in 4% buffered formaldehyde, dehydrated, and embedded
in paraffin and sequential sections was generated.
Table 1 Characteristics of patients with CF, IPF and
controls
Controls CF IPF
Sex (M/F, n) 2/6, 8 2/3, 5 6/1, 7
Age
a (years) 63 (33-76) 30 (23-38) 64 (57-70)
Current smokers (y/n) 0 0 0
Ex-smokers (y/n) 0 0 3/4
Inhaled GCS (y/n) 0 5/0 0/7
Oral GCS (y/n) 0 3/2 0/7
B2 agonist (y/n) 0 5/0 0/7
Lung function
FEV1 % of predicted
a 110 (82-141) 31 (22-45) 82 (66-93)
FEV1/(F)VC
a 86 (66-121) 50 (33-84) 90 (82-99)
VC % of predicted
a 104 (82-126) 54 (46-70) 66 (42-75)
TLC % of predicted
a ND 104 (79-129) 68 (51-90)
RV % of predicted
a ND 215 (113-318) 61 (51-101)
% TLCO SB ND 60 (50-71) 74 (51-110)
a Data are given as mean (range). M = male, F = female, GCS =
glucocorticosteroid, FEV1 = forced expiratory volume in 1 second, VC = vital
capacity. TLC = total lung capacity. RV = residual volume. TLCO = diffusing
capacity for carbon monoxide, ND = not determined.
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Page 2 of 13An initial screening of haematoxylin-stained sections was
performed to select tissue blocks encompassing regions
of fibrotic lesions, cellular inflammation, and normal tis-
sue areas. One section per tissue block was stained with
Masson’s trichrome for evaluation of gross pathological
changes.
Double Immunohistochemical Staining of MCTC and MCT
A previously validated double staining protocol was used
for simultaneous visualisation of MCTC and MCT cells
(Figure 1F) [17,22]. The staining was performed by an
automated immunohistochemistry robot (Autostainer;
Dako, Glostrup, Denmark) with EnVision™ G|2 Double-
stain System (K5361, Dako)[17]. After rehydration and
antigen retrieval, chymase-containing mast cells were
detected with an mouse anti-chymase antibody (1:100,
Novocastra, Newcastle upon Tyne, UK) a horse-radish
peroxidase(HRP)-conjugated anti-mouse secondary anti-
body and the non-permeable chromogen DAB. A double
stain blocking reagent (K5361, Dako) prevented further
recognition of anti-chymase antibodies (by chemically
destroying the antigenicity of previously applied antibo-
dies) and the remaining MCT subclass was visualised with
an mouse anti-tryptase antibody (1:12 000, Chemicon,
Temecula, CA), an alkaline phosphatase(AP)-conjugated
anti-mouse secondary antibody, and Permanent Red chro-
mogen. Sections were stained with Mayer’s haematoxylin
for visualisation of background.
Identification of Mast Cell-Related Molecules using
Immunofluorescence
A validated triple immunofluorescence protocol [17,22]
was used to simultaneously visualise the mast cell-related
molecules interleukin 6 (IL-6) or transforming growth fac-
tor beta (TGF-b)t o g e t h e rw i t hb o t hM C TC and MCT sub-
types (Table 2). After antigen retrieval and a blocking step
with 5% horse serum, the IL-6 (mouse anti-IL-6, 1:50,
Novocastra) or TGF-b (mouse anti-TGF-b, 1:40, Novocas-
tra) immunoreactivity was visualised with a horse anti-
mouse biotinylated secondary antibody and Alexa-Flour
555-conjugated streptavidin (Molecular Probes, Oregon,
USA). Next, MCT and the MCTC populations were stained
with anti-tryptase and anti-chymase antibodies that were
pre-labelled with AlexaF-488 fluorochrome and AlexaF-
350 fluorochrome, respectively (Zenon IgG1 labelling kit,
Molecular Probes).
Antibody Specificity Controls
All antibodies in the present studies have been used exten-
sively in research and routine pathological examinations of
human formalin-fixed, paraffin-embedded material; most
antibodies have also been validated and certified for
pathology-based diagnosis. For all immunohistochemical
procedures, markers and tissues, staining was absent in
sections using isotype-matched control antibodies (Dako)
that were used instead of, and in the same concentration
as, the primary antibody. The mouse monoclonal isotype
IgG1 and 2 controls are antibodies against Aspergillus
niger glucose oxidase, an enzyme which is neither present
nor inducible in mammalian tissues. The rabbit negative
control immunoglobulin fraction was isolated from serum
from healthy non-immunized rabbits.
Measurements
Quantification of Mast Cell Densities in Major Lung
Compartments
From each section double stained for MCT and MCTC,a n
ultra-high resolution digital image (> 4 GB) was generated
by an automated slide scanner robot equipped with a x20
microscope lens (ScanScope FL, Aperio, Vista, CA). Using
virtual microscopy software (Image Scope, v10.0.36.1805,
Aperio) the density of each population was quantified
manually in blinded images (CF: 20 lung blocks, 4 per
patient; IPF: 21 lung blocks, 3 per patient; controls: 16
blocks, 2 per patient) and related to the tissue area. After
manual delineation of the each analysed compartment, the
analysed tissue area was calculated through computerised
image analysis (ImageScope, Aperio, Vista, CA). Each tis-
sue section comprised > 4 cm
2 lung tissue and contained
several small airway walls, small airway lumen, pulmonary
vessel walls as well as differentially altered alveolar par-
enchyma, allowing for comparisons between the following
key compartments; Small airways: bronchioles, defined by
absence of cartilage and diameter < 2 mm. Pulmonary ves-
sels: mid-size pulmonary arteries in the broncho/bronchio-
vascular axis or with an intra-acinar localisation. The
number of vessels per section was related to the tissue
area and a mean number of vessels/mm
2 per patient were
calculated. Alveolar parenchyma: Due to the heterogeneity
of the alveolar parenchyma in CF and IPF, each slide was
assessed for mast cells in the following category of par-
enchyma: normal, or nearly normal parenchyma (defined
as absent or minimal fibrous thickening of alveolar walls
and only few scattered inflammatory cells); inflammatory
parenchyma (areas with significant leukocyte infiltration,
often accompanied by some alteration of alveolar struc-
ture); and fibrotic parenchyma (fibrotic lesions and regions
with excessive collagen deposition, as revealed by Masson’s
trichrome staining in consecutive sections). Four randomly
selected 0.5 mm
2 alveolar regions were analysed in each
lung section for each category of parenchyma. The pro-
portion (%) of the MCTC subtype in each compartment
was calculated according to (MCTC/[MCTC +M C T]) ×100.
Expression of Mast Cell-Related Molecules, IL-6 and TGF-b
The markers were selected to represent possible roles for
mast cells in chronic inflammation (IL-6) and in the for-
mation of fibrosis (TGF-b). Sections were analysed using
NIS-elements AR 3.0 system (Nikon, Tokyo, Japan), a
Nikon Eclipse 80i microscope, and a Nikon DS-Qi1Mc
camera. In triple stained sections, all tryptase- and chy-
mase-positive cells in the walls of 4 randomly selected
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Page 3 of 13Figure 1 Representative low magnification overview of a lung section from a patient with CF, stained with Masson’s trichrome
staining. Panel A-E show representative micrographs in different anatomical compartments of the lung from a patient with CF: (A) small airway,
(B) pulmonary vessel, (C) normal alveolar parenchyma, (D) region of inflammation in alveolar parenchyma and (E) region of fibrosis in alveolar
parenchyma. Consecutive sections were used for immunohistochemical double staining of tryptase-positive mast cells (MCT: permanent red) and
chymase-positive mast cells (MCTC: DAB- brown) shown to the right in each panel. F represents a close-up image (600×) of neighbouring MCTC
and MCT cells. Scale bars: Overview = 2000 μm, A-E = 100 μm. lu: airway lumen; ep: small airway epithelium; v: pulmonary vessel; and alv:
alveolar parenchyma.
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Page 4 of 13small airways, 4 pulmonary vessel walls, and 4 randomly
selected 0.5-mm
2 alveolar regions per lung section were
analysed for IL-6 and TGF-b. By subsequently dividing the
number of tryptase and/or chymase cells co-positive for
IL-6, TGF-b, respectively, by the total numbers of MCT
and MCTC, the proportion (%) of each subtype and the
total number of mast cells expressing each mast cell-
related molecule were obtained.
Measurements of degree of fibrosis
The degree of fibrosis was analysed in randomly selected
0.5 mm
2 alveolar regions stained with Masson’s trichrome,
using a scoring system for fibrosis [27]. On the same
slides, tissue density (per um
2) of collagen was assessed by
computerised image analysis using ImageScope (Aperio,
Vista, CA).
Statistical Analysis
Data were analysed statistically using Mann-Whitney
rank sum test for comparison between two groups using
GraphPad Prism v. 5 (GraphPad Software Inc., La Jolla,
CA). Data were analysed statistically using Kruskal
Wallis test with Bonferroni’s multiple comparisons test
for comparison between three groups or more. Mast cell
parameters were correlated (Spearman rank correlation
test two-tailed) to lung function and degree of fibrosis
for CF and IPF patients. Due to the low numbers of
patients, correlation analyses were also performed on
pooled CF and IPF patients. The mean number of ves-
sels per patient was correlated to mast cell parameters
within the IPF group. For all outcomes, a p-value ≤ 0.05
was considered significant (* denotes p ≤ 0.05, ** p <
0.01 and *** < 0.001).
Results
General histopathological description
Sections stained with Masson’s trichrome revealed exten-
sive alterations of lung structures in all CF and IPF patients
(Figure 1 and 2). In CF, changes of the small airways
included metaplastic and damaged epithelium, subepithe-
lial inflammation and mucopurulent plugging (Figure 1A).
The alveolar compartment was affected by structural
changes, although patchy areas of normal, or nearly nor-
mal, tissue were also present (Figure 1C). Pneumonia was
common, with infiltration of inflammatory cells in the
alveolar walls, intra-alveolar exudate (alveoli filled with
mainly neutrophils, Figure 1D) and presence of lymphoid
aggregates. Fibrotic regions were present in the adventitia
of small airways (Figure 1A) and pulmonary vessels (Figure
1B) and in the alveolar interstitium (Figure 1E). The
pathology of the IPF patients (Figure 2) was characterised
by deformation of normal lung architecture including hon-
eycombing and formation of fibrotic and fibroblast foci.
The alveolar parenchyma had widespread interstitial fibro-
sis, areas of infiltration of inflammatory cells (mostly
Table 2 Densities and proportions of mast cell populations in different lung compartments
Controls CF p-value IPF p-value
Small Airways
(mast cell/mm
2)
MCTot 357 (274-530) 89 (59-145) 0.002 357 (199-488) 0.8
MCT 332 (204-500) 65 (42-121) 0.002 197 (62-267) 0.004
MCTC 23 (17-73) 23 (9-74) 0.7 156 (114-249) 0.0003
%MCTC 6 (4-26) 30 (13-54) 0.01 52 (42-69) 0.0003
Pulmonary Vessels
(mast cell/mm
2)
MCTot 217 (124-522) 30 (24-60) 0.002 132 (89-260) 0.03
MCT 123 (38-338) 15 (6-34) 0.002 21 (9-42) 0.0006
MCTC 89 (28-185) 18 (14-26 0.002 97 (77-223) 0.05
%MCTC 46 (13-70) 59 (47-83) 0.2 84 (71-93) 0.0003
Alveolar parenchyma
(mast cell/mm
2)
Normal MCTot 28 (9-85) 58 (39-151) 0.1 65 (15-120) 0.1
MCT 26 (9-83) 52 (32-61) 0.2 54 (12-107) 0.2
MCTC 2 (0-6) 6 (3-90) 0.02 12 (2-16) 0.01
%MCTC 5 (0-11) 18 (5-60) 0.03 17 (11-18) 0.005
Inflam-matory MCTot - 96 (59-150) 0.02* 193 (74-274) 0.0006*
MCT - 73 (53-115) 0.02* 88 (15-114) 0.05*
MCTC - 7 (5-65) 0.01* 105 (59-171) 0.001*
%MCTC - 14 (4-42) 0.07* 62 (43-80) 0.001*
Fibrotic MCTot - 87 (77-137) 0.006* 192 (64-327) 0.001*
MCT - 70 (44-78) 0.07* 105 (11-181) 0.009*
MCTC - 20 (10-69) 0.004* 88 (19-147) 0.001*
%MCTC - 22 (16-51) 0.004* 49 (24-82) 0.001*
Data presented as median (range). p-value is considered significant ≤ 0.05. *Denotes comparison to normal parenchyma in control subjects.
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Page 5 of 13lymphocytes and mononuclear cells) as well as patchy
regions of structurally normal parenchyma.
Change in Densities of MCT and MCTC populations in key
anatomical compartments in CF and IPF compared to
controls
Cystic Fibrosis
In patients with CF, a significant decrease in total mast cell
density was observed in small airways. This reduction was
due to decreased MCT numbers whereas the density of
MCTC was unchanged (Figure 3A-C and Table 2). A
decrease in total mast cell numbers was observed in pul-
monary vessels. In this compartment, the density of MCT
and MCTC decreased (Figure 3D-F and Table 2). In nor-
mal areas of the parenchyma in CF affected lungs, the
total mast cell number as well as the density of MCT was
unchanged (Figure 4A-C and Table 2), however, an
increase in MCTC numbers was observed. The total num-
ber of mast cells was increased in fibrotic and inflamma-
tory areas of the alveolar parenchyma in CF patients
(Figure 4A and Table 2). In the inflammatory parenchyma
this was due to increased numbers of MCT and MCTC
whereas only the density of the MCTC population
increased in fibrotic parenchyma (Figure 4B-C and
Table 2). An increase in total mast cell numbers and the
density of MCT were found in the small airway lumen in
CF patients (MCtot: 1 0 [1-15] MC/mm
2,a n dM C T:00
[1-15] MC/mm
2) compared to controls (MCtot:0[ 0 - 1 . 7 ]
MC/mm
2, p = 0.2 and MCT: 0 0 [1,2] MC/mm
2, p = 0.2).
No difference in the density of MCTC was found between
CF patients and control subjects.
Idiopathic Pulmonary Fibrosis
In small airways of IPF patients, no change in the total
mast cell density was observed (Figure 2B and 3A). The
preserved total mast cell numbers were a result of a
decrease in MCT density and a parallel increase in MCTC
density (Figure 3A-C). A significant decrease in total mast
cell density due to decreased MCT and unchanged MCTC
was observed in pulmonary vessels (Figure 3D-F and
Table 2). In normal areas of IPF lungs, total mast cell
n u m b e r sa sw e l la st h ed e n s i t yo fM C T was unchanged
while the density of MCTC was increased (Figure 4A-C
Figure 2 Representative micrographs from a patient with IPF. Panels A-B show lung section stained with immunohistochemical double
staining for tryptase-positive mast cells (MCT: permanent red) and chymase-positive mast cells (MCTC: DAB- brown): alveolar parenchyma with
interstitial fibrosis (A) and small airway (B). Picture C shows alveolar parenchyma with interstitial fibrosis and pulmonary pleura. High density of
collagen is seen in blue with trichrome staining and picture D shows the corresponding area from a consecutive section double stained for MCT
and MCTC. In picture E lung tissue from a patient with CF is shown. High density of MPO
+ neutrophils is seen in the subepithelial tissue, in the
airway lumen (E), and in the alveolar parenchyma (F). Scale bars: A, C-D = 300 μm, B and E = 100 μm and F = 50 μm. lu: airway lumen; ep: small
airway epithelium; v: pulmonary vessel; pl: pleura and alv: alveolar parenchyma.
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Page 6 of 13and Table 2). In fibrotic parenchyma, a significant increase
in the density of the MCT and MCTC population was
detected (Figure 2A, C-D). An increase in the density of
MCTC population was found in the inflammatory parench-
yma of IPF patients, but the number of MCT was
unchanged (Figure 4B-C and Table 2).
Relative proportion of MCTC
Calculation of the MCTC percentage of the total mast
cell population revealed that there was a shift towards a
MCTC phenotype in lungs from patients with CF and
IPF (Figure 5A-C). In CF, the increase in the proportion
of MCTC cells was found in small airways, and in nor-
mal as well as fibrotic areas of parenchyma. In IPF
affected lungs, an increase in the proportion of MCTC
was found in small airways, pulmonary vessels as well as
in normal, inflammatory and fibrotic areas of the par-
enchyma (Figure 5, Figure 2A-D and Table 2).
Increased mast cell expression of IL-6 and TGF-b in CF
and IPF lungs
The results of IL-6 and TGF-b expression are shown in
Figure 6. In CF patients, the total mast cell (MCtot)
expression of IL-6 was increased in small airways (40
[25-75]%), pulmonary vessels (73 [48-83]%) and alveolar
parenchyma (30 [20-39]%) compared to controls (small
airways: 11 [0-22]%, p = 0.006; pulmonary vessels: 22 [0-
73]%, p = 0.01; and alveolar parenchyma: 8 [0-56]%, p =
0.05). No difference in mast cell expression of IL-6 was
observed in the IPF lungs compared to control subjects.
A significantly increased MCTC expression of TGF-b
was observed in all compartments analysed: IPF (small air-
ways: 84 [75-100]%, pulmonary vessels: 100 [83-100]% and
alveolar parenchyma: 100 [50-100]%) and controls (small
airways: 8 [0-50]%, p = 0.0008; pulmonary vessels: 0 [0-
50]%, p = 0.005; and alveolar parenchyma: 0 [0-20]%, p =
0.004). A similar increase in TGF-b expression was
observed in the MCTC population in CF patients.
When dividing the alveolar parenchyma of CF and IPF
patients in normal, inflammatory and fibrotic regions, no
difference in mast cell expression of TGF-b was found
between the different types of parenchyma. The mast cell
expression of IL-6 was high in seemingly normal and
inflammatory regions of the parenchyma. However, IL-6
expression in mast cells was significantly lower in fibrotic
parenchyma compared to normal and inflammatory
regions of the CF lung parenchyma (Figure 7).
Correlation of mast cell parameters to lung function and
degree of fibrosis
Some mast cell parameters correlated significantly with
lung function values of the CF and IPF patients. As an
example, the percentage of MCTC in small airways corre-
lated negatively with FEV1/VC. Also the density of MCTC
per mm
2 in fibrotic alveolar parenchyma correlated nega-
tively with FEV1 % predicted (ps = -0.83, p = 0.003). The
mast cell expression of TGF-b in different compartment
correlated negatively with several lung function values.
There were negative correlation between the expression
of TGF-b in small airways and FEV1/VC (ps = -0.90,
Figure 3 Total mast cell densities (A, D) and densities of each subtype, MCT (B, E) and MCTC (C, F), in lung tissue compartments of
never-smoking controls and patients with CF and IPF. Data are presented as mast cells per mm
2 lung tissue and presented for small airways
(A-C) and pulmonary vessels (D-F). Horizontal line denotes median value. Data are expressed as scatter plots where horizontal lines denote
median values. Statistical differences to never-smoking controls using Mann-Whitney where * denotes p < 0.05, and ** p < 0.01.
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Page 7 of 13p = 0.005) as well as between expression of TGF-b in pul-
monary vessels and FEV1 % predicted (ps = -0.86, p =
0.01). Within the IPF group, FEV1/VC and the propor-
tion of MCT in pulmonary vessel walls correlated nega-
tively (rs = -0.87, p = 0.03). There was also a tendency for
a negative correlation between FEV1 and the proportion
of MCTC in fibrotic parenchyma (rs = -0.83, p = 0.06). In
alveolar parenchyma in CF and IPF patients, the density
as well as the percentage of MCTC correlated positively
with the degree of fibrosis (ps = 0.73, p < 0.0001 and ps =
0.66, p < 0.0001, respectively) and the density of collagen
(ps = 0.72, p < 0.0001 and ps = 0.68, p < 0.0001, respec-
tively). Since mast cells may contribute to vascular remo-
delling and angiogenesis, mast cell parameters were
correlated to the number of vessels per patient. In IPF
patients, the number of vessels/mm
2 and the density of
MCTC/mm
2 in fibrotic parenchyma showed a correlation
of rs = -0,75 and p = 0,06.
Discussion
The present study provides further insight into the mast
cell involvement in CF and IPF by providing a detailed
characterisation of how each of the major mast cell
populations are distributed in the major lung compart-
ments and how they relate to distinct pathologies,
including fibrotic lesions. Apart from changes in densi-
ties, distribution, and expansion of MCTC,b o t hM C T
and MCTC populations displayed an altered expression
of IL-6 and TGF-b. Moreover, we show correlations
between the increased density of MCTC and degree of
fibrosis in CF and IPF patients.
Although the present study produced clear and con-
clusive results, the study has some limitations that need
to be discussed. All control patients in the present study
were undergoing lobectomy for suspected lung cancer.
Theoretically the presence of a tumour might have an
effect on mast cell properties. To partly overcome this
problem we analysed only lung regions collected far
from the tumour, a procedure has commonly been used
to collect human control tissue [25,28]. Furthermore, we
compared the control tissue in the present study with a
separate material of bronchial and transbronchial biop-
sies from completely healthy subjects and have found no
differences in mast cell parameters [22,29]. Due to diffi-
culties in obtaining the present type of immediately
fixed lung tissue, the number of patients in the CF
group was relatively low. Yet, many of the mast cell
parameters were markedly and statistically altered in IPF
and CF compared to controls. The lack of statistical dif-
ferences between the study groups, however, must be
interpreted with cautiousness (although we have per-
f o r m e dap o w e rs t u d yf o rt h en o n - s i g n i f i c a n tr e s u l t s
that showed that for most parameters the power is suffi-
cient to rule-out any clear alterations in the absence of
Figure 4 Mast cell densities in alveolar parenchyma from
never-smoking controls and patients with CF and IPF. Data are
presented as mast cells per mm
2 lung tissue. The total mast cell
densities (A) and densities of each subtype, MCT (B) and MCTC (C),
are presented in regions of normal, inflammatory and fibrotic
alveolar parenchyma in each disease. Data are expressed as scatter
plots where horizontal lines denote median values. Statistical
differences to never-smoking controls using Mann-Whitney where *
denotes p < 0.05, ** < 0.01, and *** p < 0.001.
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Page 8 of 13statistical differences). To partly compensate for the lim-
ited patient numbers in the present study, the strategy
was indeed to, for each patient, perform a detailed char-
acterisation of mast cells in multiple lung regions and,
in addition, in each tissue block also study numerous
sub-compartments subjected to different types of
pathologies.
Our demonstration of a shift in the balance between
the mast cell subtypes in the analysed compartments,
with a several-fold increase in the percentage of the
MCTC subtype in fibrotic lesions represents a key finding
in the present study. Similar expansion of the MCTC
population has also been observed in other respiratory
diseases like asthma [18] and COPD [17]. The expansion
of the MCTC population in CF and IPF may have numer-
ous implications in lung remodelling processes. In sup-
port of this, Hirata et al. [20] showed increased chymase
expression in human idiopathic interstitial pneumonia,
correlated with increased numbers of IL-4 expression
cells, smooth muscle cells and myofibroblasts. Further-
more, Tchougounova et al. [30] demonstrated a possible
role for chymase in mMCP-4 knockout mice, where chy-
mase-deficient mice developed an imbalance in extracel-
lular matrix production. Increased chymase expression
and mast cell involvement have also been demonstrated
lung vascular remodelling in pulmonary hypertension
[31,32]. In IPF patients, we found a tendency for a nega-
tive correlation between the number of vessels/mm
2 and
the density of MCTC.
Increased numbers of mast cells have been found in
animal models of fibrosis [33,34] and mast cells have
been shown to affect biochemical properties of lung
fibroblast function in vitro [2,4,35]. Increased numbers of
mast cells in patients with fibrotic lung disorders have
Figure 5 The proportion of MCTC and MCT, expressed as the percentage of MCTC, in anatomical lung compartments in never-smoking
controls and patients with CF and IPF. Data are presented for small airways (A), pulmonary vessels (B), and alveolar parenchyma (C). Data are
presented as scatter plots, where horizontal lines denote median values. Statistical differences to never-smoking controls were analysed using
Mann-Whitney and asterisks show significant difference where * denotes p < 0.05, ** < 0.01, and *** p < 0.001.
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Page 9 of 13been described by others [14,21] and some studies
described a association to the degree of fibrosis [15].
Hubeau et al[12] found unaltered mast cell numbers in
the conducting airways in CF lungs. Unfortunately, other
compartments of the lung were not included in this
investigation. Little is currently known regarding the
recruitment mechanisms of mast cells to diseased areas
of the lung [36]. Mast cell progenitor recruitment to the
airways is dependent on integrins and mediated by sev-
eral chemotactic factors (chemokines, leukotrienes etc.)
[37-39]. For example, mast cells have been shown to
adhere to airway smooth muscle via cell adhesion mole-
cule-1 (CADM1) through activation of the CXCR3/
CXCL10 axis [40,41]. This is an important filed of
research for completely elucidating the role of mast cells
in disease.
Due to the differences in pathogenesis in CF and IPF,
we have avoided making any direct comparisons of the
two diseases. Although CF and IPF have different etiolo-
gies, the basic pathological features of the fibrotic lesions
include excessive collagen deposition. Our data show
that mast cells infiltrate these regions. We showed strong
statistical correlations between increased densities of
MCTC cells, degree of fibrosis and parenchymal collagen
density. These observations points toward a role for mast
cells in the pathogenesis of fibrotic lesions and is further
supported by our observation that expression of TGF-b,
was increased in the MCTC population in CF and IPF
Figure 6 Expression patterns of interleukin (IL)-6 (A-C), and TGF-b (D-F) in small airways, pulmonary vessels, and alveolar parenchyma.
In each graph, results are shown as the percentage of total mast cells, and of MCTC and MCT subtypes that are positive for the respective
mediator. Data are expressed as medians with interquartile ranges. Statistical differences to never-smoking controls were analysed using Mann-
Whitney and asterisks show significant difference where * denotes p < 0.05, ** < 0.01, and *** p < 0.001. Representative micrographs of triple
staining of mast cell subtypes and TGF-b (G-I). Arrows indicate tryptase and TGF-b co-localisation and * indicates co-localisation of tryptase,
chymase and TGF-b.
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Page 10 of 13lungs. The importance of TGF-b as a fibrotic agent in the
lung has been widely demonstrated [42,43]. An increased
expression of TGF-b has been documented during tissue
remodelling in several chronic lung diseases including CF
[44] and in IPF [45]. In mice and rat lungs a severe fibro-
tic response develops in the lung after induction of active
TGF-b [46,47]. Injuries of human lung tissue induced by
different stimuli including bacteria lead to an induction
of TGF-b,w h i c hp l a y sak e yr o l ei nm e d i a t i n gt i s s u e
remodelling and repair. TGF-b,w h e ne x p r e s s e di nt h e
airways stimulates fibroblasts to produce extracellular
matrix proteins [43,48].
M a s tc e l l si nC Fa n dI P Fl u n g sm a ya l s op a r t i c i p a t ei n
inflammatory events. Although lung tissue in both CF and
IPF lungs contained such areas, the nature of the inflam-
mation was different. In accordance with the published lit-
erature, IPF lungs showed scattered areas with mild
chronic inflammation with lymphocyte and mononuclear
cell infiltrations, whereas CF lungs displayed a neutrophilic
inflammation with signs of on going tissue destruction.
The pro-inflammatory cytokine IL-6 was selected as an
indicator of an “inflammatory” mast cell phenotype in this
study. In CF lungs, both MCT and MCTC populations
show elevated expression of IL-6 in all compartments
investigated. IL-6 is a multifunctional regulator of immune
and inflammatory processes [49] and is a potent chemo-
attractant for neutrophils. In rat peritoneal mast cells it
has been demonstrated that LPS, released from gram
negative bacteria, induce IL-6 activation in absence of clas-
sical degranulation [50]. Therefore, during bacterial infec-
tions, a hallmark of CF, mast cells could via TLR receptors
act as a source of IL-6 and other pro-inflammatory cyto-
k i n e ss u c ha sI L - 1 ,I L - 8 ,a n dG R O - a.T h el o w e re x p r e s -
sion of IL-6 in IPF could indicate less active inflammation
and lack of bacterial infections.
In the present study the density change of mast cell
populations and altered MCTC/MCT balance was in the
lung parenchyma restricted to areas affected by either
fibrosis or cellular inflammation. Mast cells co-cultured
with fibroblasts have been shown to induce collagen
synthesis and stimulate fibroblast proliferation [2,4,35]. In
relevance to the present study, co culturing of mast cells
and fibroblasts induced a change in mast cell phenotypes,
from MCT to MCTC [4]. This may indicate that the con-
tact between mast cells and fibroblasts activate the cells
involved, inducing processes leading to fibrosis and that
MCTC plays an important role in this process. However,
t h ee l e v a t e de x p r e s s i o no fm a s tc e l lI L - 6a n dT G F - b was
present also in seemingly normal regions of the diseased
lung. This observation suggests that, in the case of IPF,
mast cells acquire a pro-fibrotic, high TGF-b expressing
phenotype even prior to the formation of fibrotic regions.
Similarly, in CF the elevated IL-6 expression in less
affected regions suggests that mast cell activation in this
disease may take place early in the pathogenesis. In sup-
port of this, based on findings of increased lung mast cell
numbers already in CF foetuses, it has been speculated
that mast cells may participate even in the initiation of the
inflammation and lung histopathology in CF [51].
Medical treatment might have contributed to the
change in MCTC/MCT proportion observed in the CF
patients. Steroids have been demonstrated to reduce
mast cell numbers and mainly affect the MCT population
i nv a r i o u sc o m p a r t m e n t so ft h el u n g[ 5 2 ] .A l lC F ,b u t
none of the IPF patients included in the study were trea-
ted with inhaled steroids and most of them with oral
steroids. In CF patients this could be one explanation to
the decrease in cell numbers in small airways and pul-
monary vessels, accessible to steroids. However, the
almost extinct mucosal mast cells in pulmonary vessels
Figure 7 Mast cell expression of IL-6 in parenchyma in patients with CF (A), and mast cell expression of TGF-b in parenchyma in IPF
patients (B). Overall significance for total mast cell expression in different parenchyma is shown in each picture. Significance to healthy controls
is shown as: p < 0.05 for total mast cell expression (*), as well as MCT (#) and MCTC (+), and to normal CF parenchyma as: p < 0.05 for total mast
cell expression (×) and MCT (●).
Andersson et al. Respiratory Research 2011, 12:139
http://respiratory-research.com/content/12/1/139
Page 11 of 13in CF may have other causes since a similarly robust
reduction was seen in the untreated IPF patients. Regard-
less of treatment, increased mast cell numbers, particu-
larly the MCTC population, in fibrotic and inflammatory
region of the alveolar parenchyma was demonstrated in
both CF and IPF patients. This might be explained by a
particularly strong mast cell promoting milieu in the dis-
eased parenchyma.
Conclusions
In conclusion, the present study has demonstrated that
increased numbers of altered MCT and MCTC mast
cells infiltrate diseased regions of CF and IPF lungs.
These results thus identify mast cell alterations as a
significant and distinct part of the histopathology in
CF and IPF. With mast cells being capable of partici-
pating in a both pro- and anti- inflammatory and
fibrotic processes, explorations of the role of mast cells
in CF and IPF lungs emerges as an important field of
research for identifying novel strategies to combat
these disorders.
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